𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment selection after imatinib resistance in chronic myeloid leukemia

✍ Scribed by Elias Jabbour; Jorge Cortes; Hagop Kantarjian

Book ID
107384341
Publisher
Springer-Verlag
Year
2009
Tongue
English
Weight
158 KB
Volume
4
Category
Article
ISSN
1776-2596

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

O36 Factors of imatinib resistance in ch
O36 Factors of imatinib resistance in chronic myeloid leukemia
✍ B. KajtΓ‘r; D. AlpΓ‘r; J. TΓ³th; R. LΓ‘szlΓ³; P. JΓ‘ksΓ³; L. Kereskai; Z. Nagy; L. Pajo πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 49 KB

Hb-Hana family is the first described example, where partial glutathione reductase deficiency represents a modifying factor of clinical manifestation of unstable hemoglobinopathy. Grant support: MSM 6198959205 and MSM 6198959216. O35 A prognostic impact of transfusion dependency on survival of pati

Philadelphia-negative acute myeloid leuk
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
✍ Carmen Fava; Jorge Cortes πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 306 KB πŸ‘ 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf